Photo: taiwannews.com.tw
Sanofi Reports 7% Q3 Sales Growth, Driven by Strong Pharma Performance
Sanofi reported a robust 7% Q3 sales growth, driven by exceptional pharmaceutical performance, with Dupilumab sales surpassing €4 billion for the first time, indicating strong market demand.
- In Q3 2025, Sanofi achieved a sales growth of 7.0% at CER, with business earnings per share (EPS) reaching €2.91, reflecting the companys financial resilience.
- Sales of newly launched pharmaceuticals surged by 57.1%, totaling €1.0 billion, significantly bolstered by the performance of ALTUVIIIO and Dupilumab, which drove overall growth.
- Despite strong pharmaceutical sales, Sanofis vaccines sales experienced a decline of 7.8% to €3.4 billion, primarily due to reduced demand for influenza vaccines during the quarter.
Por Qué Es Relevante
The 7% sales growth highlights Sanofis successful adaptation to market dynamics, particularly in the pharmaceutical sector, as evidenced by the impressive performance of Dupilumab. This trend underscores the growing importance of innovative treatments in driving revenue and may influence future investments in research and development across the industry.